Welcome to our dedicated page for Taro Pharmaceutical Inds news (Ticker: TARO), a resource for investors and traders seeking the latest updates and insights on Taro Pharmaceutical Inds stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Taro Pharmaceutical Inds's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Taro Pharmaceutical Inds's position in the market.
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) will release its financial results for the year ending March 31, 2021, on May 19, 2021. The financial report will be made available on Taro's official website. The company is focused on producing high-quality healthcare products through research, development, manufacturing, and marketing. For more information, visit www.taro.com.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) reported unaudited financial results for Q3 and nine months ending December 31, 2020. Q3 net sales fell to $140.1 million, a $7.5 million decline year-over-year. Gross profit dropped to $73.2 million (52.2% of sales), impacted by price erosion and COVID-19. Net income plummeted to $32.9 million, down $34.8 million from the prior year. For nine months, net sales of $400.6 million represented a $69.2 million decrease, with a significant operating loss of $(371.9) million due to a $478.9 million one-time settlement charge. Despite challenges, the company continues its R&D investment.
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) will announce its financial results for the quarter and nine months ending December 31, 2020, on January 27, 2021, after market close. The results will be available on Taro's website, www.taro.com. Taro is a multinational pharmaceutical company dedicated to high-quality healthcare products through discovery, development, manufacturing, and marketing.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) reported unaudited financial results for Q2 and six months ending September 30, 2020. Net sales fell to $142.8 million, down $18 million year-over-year, with a gross profit of $81.6 million (57.1% of sales), a decline of $20 million. Operating income dropped to $41 million, decreased by $21.6 million. A significant one-time charge related to DOJ investigations led to an operating loss of $408.2 million for six months, compared to a profit of $131.1 million last year. Net loss attributed to Taro stood at $(389.8) million, resulting in a diluted loss per share of $(10.19).
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) will release its financial results for the quarter and six months ended September 30, 2020, on October 28, 2020. An earnings call is scheduled for October 29, 2020, at 8:00 am ET, where management will discuss the company’s performance and answer questions. Interested parties can access the earnings release on Taro’s website. Additionally, a replay of the conference call will be available from October 29 to November 5, 2020.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced the launch of a new specialty generic, deferiprone, an iron chelator for patients with transfusional iron overload due to thalassemia syndromes. This expands Taro's specialty product portfolio. Deferiprone, a generic version of Ferriprox®, will be exclusively dispensed by BioPlus Specialty Pharmacy. The approval was based on serum ferritin level reduction, though no controlled trials showed direct benefits in disease symptoms. Important safety warnings include risks of agranulocytosis and neutropenia.